ResMed Inc.

RSS Feed
ResMed is a holding company. Through its operating subsidiaries, the company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software solutions that diagnose, treat and manage respiratory disorders including sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The company has two operating segments: Sleep and Respiratory Care and Software-as-a-Solutions. The company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators and cloud-based software informatics solutions.
  • TickerRMD
  • ISINUS7611521078
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States
SmartInsider

ResMed Inc: 1 director

A director at ResMed Inc sold 2,500 shares at 212.840USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

EUR 8.34
Corporate Voice
Health Care
ResMed Inc.
3d 3d / 5h / 41m 1 EN
TheScreener

RESMED suffers a double requalification, which weighs heavily on its rating, now at Neutral.

The independent financial analyst theScreener just downgraded the general evaluation of RESMED (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Neutral. As of the analysis date April 30, 2021, the closing price was USD 187.97 and its target price was estimated at USD 168.56.

EUR 12.50
Quant
Health Care
ResMed Inc.
47d 01/05/2021 6 EN
GlobeNewsWire

ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021

ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021 SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast. Earnings webcast details:     • Location:        • Date:   Thursday, April 29, 202...

Free
Corporate Voice
Health Care
ResMed Inc.
70d 08/04/2021 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Equity
Personal & Household Goods
ATVI , ALXN ...
1y 06/04/2020 40 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

EUR 208.40
Chart
Technology
VNET , AAON ...
1y 17/03/2020 62 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

EUR 208.40
Chart
Technology
VNET , AAON ...
1y 17/03/2020 62 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.68
Chart
Health Care
ABBV , ATVI ...
1y 20/02/2020 24 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.68
Chart
Automobiles & Parts
ADNT , AMZN ...
1y 03/02/2020 21 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.68
Chart
Technology
AGYS , APD ...
1y 02/02/2020 25 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

• A number of Consumer Cyclical names continue to indicate leadership. (ex. THO, WGO, CROX, WLH, LEN, KBH, PZZA, TXRH, SCVL, GCO, and RH) • The Healthcare Sector has a number of attractive names developing major bases and staging RS reversals. (ex. CAH, HSIC, ITGR, ABT, MLAB, RMD, SYK, MD, RDNT, TRHC, CNC, WCG, RGNX, BEO, and SYNH) • The Technology Sector continues to be long-term leadership. Many issues are extended and we would suggest taking opportunity of any weakness. (ex. TER, AMAT, SYNA, INTC, AVGO, INTU, LPSN, CTXS, ADP, EXLS, PRSP, and FN)

EUR 41.68
Chart
Health Care
ABT , ALLE ...
1y 27/01/2020 26 EN
SmartInsider

ResMed Inc: 1 director

A director at ResMed Inc sold 2,500 shares at 212.840USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

EUR 8.34
Corporate Voice
Health Care
ResMed Inc.
3d 3d / 5h / 41m 1 EN
GlobeNewsWire

ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021

ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021 SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast. Earnings webcast details:     • Location:        • Date:   Thursday, April 29, 202...

Free
Corporate Voice
Health Care
ResMed Inc.
70d 08/04/2021 1 EN
BusinessWire

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2018

SAN DIEGO--(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD) today announced results for its quarter ended March 31, 2018. Revenue for the quarter was $591.6 million, a 15 percent increase compared to the same period of the prior year. “We had a strong quarter, with solid revenue growth at the top line, and operating leverage improving the bottom line,” said ResMed CEO Mick Farrell. “Our cloud-connected medical device strategy is succeeding; the major markets for our sleep business are adopting remote monitoring systems, which ...

Free
Corporate Voice
Health Care
ResMed Inc.
3y 26/04/2018 1 EN
BusinessWire

Company Profile for ResMed

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ...

Free
Corporate Voice
Health Care
ResMed Inc.
3y 06/04/2018 1 EN
BusinessWire

ResMed nomme Bobby Ghoshal au poste de directeur principal de la technologie

SAN DIEGO--(BUSINESS WIRE)-- ResMed (NYSE : RMD, ASX : RMD) a annoncé aujourd’hui la prise de fonctions immédiate de Bobby Ghoshal au poste de directeur principal de la technologie (CTO, pour Chief Technology Officer, en anglais). Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20180402005858/fr/ Bobby Ghoshal, ResMed Chief Technology Officer (Photo: Business Wire) En tant que CTO, M. Ghoshal dirigera l’équipe mondiale d’informatique de santé et d’ana...

Free
Corporate Voice
Health Care
ResMed Inc.
3y 02/04/2018 1 FR
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Equity
Personal & Household Goods
ATVI , ALXN ...
1y 06/04/2020 40 EN
Fundamental Research
Sid Rajeev

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 16.67
Equity
1PG , DRI ...